$537.51
-5.11-0.94%
Dern. MÀJ: Nov 13, 11:56 AM
Vertex Pharmaceuticals rose 24.9% from $434.52 to $542.62, ahead of the S&P 500's +12.7%. Its worst day was Jul 8 (−4.6%), and its low came Nov 19 at $421.03.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Vertex Pharmaceuticals closed at its lowest level of the year, 3.1% below where the year started.
−3.3% · S&P 500 +0.4%
Morgan Stanley moved Vertex Pharmaceuticals from Equal-Weight to Overweight and lifted its price target from $438.00 to $516.00; shares rose 6.8%.
Story events cover the past 12 months · Times ET
+6.8% · S&P 500 +0.1%
EPS of $5.03 beat the $4.85 estimate on $3.2B revenue (est. $3.2B); FY revenue guidance of $12.9B–$13.1B against the $13.0B consensus.
+5.7% · S&P 500 +0.1%
- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically
+8.3%, the year's best day · S&P 500 −0.2%
EPS of $4.47 beat the $4.18 estimate on $3.0B revenue (est. $3.0B); FY revenue guidance of $12.9B–$13.1B against the $13.0B consensus.
−1.3% · S&P 500 +0.8%
Vertex Pharmaceuticals shares rose 6.0%, while the S&P 500 fell 0.1%.
+6.0% · S&P 500 −0.1%
EPS of $4.73 beat the $4.63 estimate on $3.3B revenue (est. $3.2B); FY revenue guidance of $13.1B–$13.2B against the $13.0B consensus.
+1.7% · S&P 500 +1.8%
EPS of $4.76 beat the $4.70 estimate on $3.4B revenue (est. $3.4B); FY revenue guidance of $13.2B–$13.3B against the $13.3B consensus.
−4.0% · S&P 500 +0.3%
Where it ended: a close of $542.62 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $4.00, revenue est. $3.5B).
Nothing in the past 12 months.
All VRTX dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VRTX and SPY from Benzinga historical bars. Not investment advice.